How does Alecensa (alectinib) work?
Alecensa (alectinib) is a targeted cancer medicine that blocks the ALK (anaplastic lymphoma kinase) protein. It does this by inhibiting ALK signaling inside cancer cells, which helps stop tumor growth and spread in patients whose tumors have ALK gene rearrangements. [1]
What happens after ALK is blocked?
When ALK signaling is inhibited, downstream pathways that normally drive cell survival and proliferation are turned down. The effect is reduced cancer cell growth and increased sensitivity to cell death mechanisms, depending on the tumor’s biology. [1]
Does Alecensa target any other receptors besides ALK?
Alecensa is best described as an ALK inhibitor. The mechanism described for Alecensa centers on blocking ALK-driven signaling in ALK-rearranged cancers. [1]
Why does this mechanism matter for ALK-positive NSCLC?
In ALK-positive non-small cell lung cancer (NSCLC), tumor cells depend on ALK activity for growth. Blocking ALK can therefore produce tumor shrinkage and disease control, which is why ALK rearrangement status is used to select patients for treatment. [1]
Key safety-related question people ask: does the mechanism affect side effects?
Because Alecensa acts on ALK-related signaling in cancer cells, it can also influence biological processes where ALK signaling contributes elsewhere in the body, which is one reason side effects can occur even though the intent is targeted therapy. [1]
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/